open access

Vol 9, No 2 (2020)
Case reports
Published online: 2020-02-07
Get Citation

Long term management challenges in diabetic patients with rhino-orbito-cerebral mucormycosis

Nishesh Jain, Sri Venkata Madhu
DOI: 10.5603/DK.2020.0005
·
Clinical Diabetology 2020;9(2):138-140.

open access

Vol 9, No 2 (2020)
Case reports
Published online: 2020-02-07

Abstract

There has been a recent upsurge in prevalence of diabetes mellitus in developing world. This has resulted in exponential increase in the incidence of both communicable and non-communicable diseases. Some of the infections increase morbidity and mortality associated with diabetes. Rhino-orbital-cerebral mucormycosis (ROCM) is one of the fatal opportunistic infections in diabetes. There is little data published regarding the short and long term management of patients suffering from this invasive fungal infection. Hereby, we report few cases of ROCM with varied presentations and their short and long term follow up. These patients were initially treated with injectable amphotericin B and later followed up with oral posaconazole.

Abstract

There has been a recent upsurge in prevalence of diabetes mellitus in developing world. This has resulted in exponential increase in the incidence of both communicable and non-communicable diseases. Some of the infections increase morbidity and mortality associated with diabetes. Rhino-orbital-cerebral mucormycosis (ROCM) is one of the fatal opportunistic infections in diabetes. There is little data published regarding the short and long term management of patients suffering from this invasive fungal infection. Hereby, we report few cases of ROCM with varied presentations and their short and long term follow up. These patients were initially treated with injectable amphotericin B and later followed up with oral posaconazole.

Get Citation

Keywords

diabetes, posaconazole, rhino-orbital-cerebral mucormycosis

About this article
Title

Long term management challenges in diabetic patients with rhino-orbito-cerebral mucormycosis

Journal

Clinical Diabetology

Issue

Vol 9, No 2 (2020)

Pages

138-140

Published online

2020-02-07

DOI

10.5603/DK.2020.0005

Bibliographic record

Clinical Diabetology 2020;9(2):138-140.

Keywords

diabetes
posaconazole
rhino-orbital-cerebral mucormycosis

Authors

Nishesh Jain
Sri Venkata Madhu

References (7)
  1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017; 128: 40–50.
  2. Guinea J, Escribano P, Vena A, et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS One. 2017; 12(6): e0179136.
  3. Peleg AY, Weerarathna T, McCarthy JS, et al. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007; 23(1): 3–13.
  4. Giudice G, Cutrignelli DA, Sportelli P, et al. Rhinocerebral mucormycosis with orosinusal involvement: diagnostic and surgical treatment guidelines. Endocr Metab Immune Disord Drug Targets. 2016; 16(4): 264–269.
  5. Pfaller MA, Messer SA, Hollis RJ, et al. SENTRY Participants Group, SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002; 46(4): 1032–1037.
  6. Yoon YK, Kim MJa, Chung YGu, et al. Successful treatment of a case with rhino-orbital-cerebral mucormycosis by the combination of neurosurgical intervention and the sequential use of amphotericin B and posaconazole. J Korean Neurosurg Soc. 2010; 47(1): 74–77.
  7. Whaley SG, Berkow EL, Rybak JM, et al. Azole Antifungal Resistance in and Emerging Non- Species. Front Microbiol. 2016; 7: 2173.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl